source
- Summit pulls $500M share sale a day after announcing itThe developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones.BioPharma Dive · 1mo ago↗ source
- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyA strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss.BioPharma Dive · 1mo ago↗ source
- STAT+: A suspicious denial pattern in Medicare AdvantageMajor Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.STAT · 1mo ago